Article
Succinate dehydrogenase deficiency in a PDGFRA mutated GIST.
BMC cancer - 2 Aug 2017
Belinsky Martin G, Cai Kathy Q, Zhou Yan, Luo Biao, Pei Jianming, Rink Lori, von Mehren Margaret
Abstract excerpt
BACKGROUND: Most gastrointestinal stromal tumors (GISTs) harbor mutually exclusive gain of function mutations in the receptor tyrosine kinase (RTK) KIT (70-80%) or in the related receptor PDGFRA (~10%). These GISTs generally respond well to therapy with the RTK inhibitor imatinib mesylate (IM), although initial response is genotype-dependent. An alternate mechanism leading to GIST oncogenesis is deficiency in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
